Optibrium Publishes Major Peer-Reviewed Study
on AI Applications to Global Pharma Data
Published in AI Letters, the study collaborators Optibrium, Takeda and Intellegens, demonstrated the application of deep learning imputation to a global pharma dataset, offering new insights into drug discovery data that transform how complex data can be used to identify opportunities for new drugs and streamline the drug discovery process.
CAMBRIDGE, UK, 29 June 2021 – Optibrium Limited, leading provider of software and artificial intelligence (AI) solutions
for drug discovery, today announced the publication of a peer-reviewed study in Applied AI Letters, “Deep Imputation
on Large-Scale Drug Discovery Data” .
Working with Takeda Pharmaceuticals’ proprietary global dataset, the team applied Optibrium’s Augmented
Chemistry® platform, demonstrating the potential of deep learning imputation to reduce cost and improve success rates
of drug discovery. The platform leverages the Alchemite™ deep learning method , developed by Intellegens, and
shown to deliver more accurate and reliable predictions of complex biological properties of potential drugs, enabling
more effective design decisions.
The study demonstrated that deep learning imputation generates new and valuable insights on global pharma-scale,
high-value and proprietary datasets. Such datasets are complex, with data deriving from many different experiments,
including compound activities in biochemical and phenotypic assays, high-throughput screening data and absorption,
distribution, metabolism, elimination, and toxicity (ADMET) endpoints.
Furthermore, the method reliably identified the most accurate predictions on which to base decisions, which is essential
to avoid missing valuable opportunities arising from inaccurate predictions. It highlighted where more experimental
data are required to make a confident decision, setting it apart from other machine learning and AI methods that
struggle to provide reliable confidence information on individual predictions .
Following on from a previous study , which demonstrated the effectiveness of deep learning imputation on smaller
project-specific datasets, this new study showed that the same method scales to global pharma datasets. The described
model was built on 1.8 million data points relating to approximately 700,000 compounds and 1,200 experimental
endpoints. When applied on this scale, the insights into high-value compounds and research strategies increase
Matthew Segall, CEO at Optibrium, said: “This study corroborates the tremendous results we have seen in many
collaborations with pharma, biotech and not-for-profit organisations. We are excited to see the significant benefits our
AI technology is producing and the enthusiasm for its uptake in the pharma community.”
To view a webinar summarising the key results of this study, visit https://bit.ly/largescale_imputation.
For further information on Optibrium, please visit www.optibrium.com, contact [email protected] or call +44 1223815900.
 Irwin et al. (2021) App. AI Lett. DOI: 10.1002/ail2.31
 T. Whitehead et al. (2019) J. Chem. Inf. Model. 59(3) pp. 1197-1204.
 Hirschfeld et al. (2020) J. Chem. Inf. Model. 60(8) pp. 3770-3780
 Irwin et al. (2020) J. Chem. Inf. Model. 60(6) pp. 2848–2857